Crossmark

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening

Crossref DOI link: https://doi.org/10.1038/s41598-023-35950-7

Published Online: 2023-06-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Haldrup, Jakob

Weiss, Simone

Schmidt, Linnéa

Sørensen, Karina Dalsgaard
Funding

Funding for this research was provided by:

Harboefonden

Aarhus University, Graduate School of Health

Novo Nordisk Fonden
License Information

Text and Data Mining valid from 2023-06-03

Version of Record valid from 2023-06-03
More Information

Article History

Received: 19 September 2022

Accepted: 26 May 2023

First Online: 3 June 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below